title: The significance of bone marrow involvement in aggressive lymphomas: A retrospective comparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B cell lymphoma in China.
abstract: BACKGROUND
  Peripheral T cell lymphomas (PTCL) have been demonstrated to have a poorer prognosis than diffuse large B cell lymphoma (DLBCL) due to a high frequency of bone marrow involvement (BMI). However, the clinical characteristics of PTCL with BMI have not been fully described, and the clinical outcomes of PTCL with BMI and DLBCL with BMI have not been well compared.
  
  
  METHODS
  The clinical characteristics and survival of 25 nodal PTCL cases with BMI and 42 DLBCL cases with BMI were compared.
  
  
  RESULTS
  Most of the PTCL patients with BMI had lymphadenopathy (88%), B symptoms (76%), an elevated LDH level (68%), anemia (64%), splenomegaly (60%), and a poor performance status (52%). Except for the differences of lymphadenopathy and thrombocytopenia between PTCL with BMI and DLBCL with BMI, similarities in gender, age, hepatomegaly, splenomegaly, a bulky mass, B symptoms, elevated LDH, ≥2 extranodal sites, ECOG scores ≥2, anemia, and international prognostic index (IPI) and age-adjusted IPI scores were observed between the 2 groups. The 2 groups also had similar 3-year overall survival (25.8 vs. 30.0%, p = 0.846) and progressive-free survival (21.3 vs. 25.2%, p = 0.815) rates.
  
  
  CONCLUSIONS
  PTCL with BMI have a similar aggressive course and poor survival compared to DLBCL with BMI. Thus, the immunophenotype of either T or B lineage may not be a crucial prognostic indicator of survival for these 2 aggressive lymphomas.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
authors.forename: Shuhua
authors.initials: S
authors.lastname: Yi
authors.forename: Gang
authors.initials: G
authors.lastname: An
authors.forename: Junyuan
authors.initials: J
authors.lastname: Qi
authors.forename: Dehui
authors.initials: D
authors.lastname: Zou
authors.forename: Yaozhong
authors.initials: Y
authors.lastname: Zhao
authors.forename: Peihong
authors.initials: P
authors.lastname: Zhang
authors.forename: Huishu
authors.initials: H
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Lugui
authors.initials: L
authors.lastname: Qiu
mesh_terms: D000368:Aged; D015992:Body Mass Index; D001853:Bone Marrow / Q000473:pathology*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000473:pathology / Q000628:therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D007770:L-Lactate Dehydrogenase